COVID-19 Antibody Response in Patients with Thalassemia

Background The coronavirus disease 2019 (COVID-19) can severely affect people with comorbidities such as those with diabetes, hypertension, chronic lung disease, cancer, and hemoglobinopathies. Studies assessing the clinical characteristics and immune response to COVID-19 infection in patients with thalassemia are limited. Objectives The primary objective of the study was to study the clinical pattern and the immunoglobulin G (IgG) antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with transfusion-dependent thalassemia (TDT) compared to patients without thalassemia. The secondary objective wasto study the relationship of COVID-19 severity with IgG antibody titers. Setting, Design, and Participants This case-control study was conducted at a tertiary care hospital between January 2021 and August 2022. A total of 30 patients with TDT (mean age: 12.7 years, SD: 4.7) and 30 patients without thalassemia (mean age: 13.9 years, SD: 7) who tested positive for COVID-19 in the preceding six weeks were recruited. Methods Serum samples from the cases and controls were collected after 6, 12, and 24 weeks of COVID-19 infection for IgG antibody estimation using chemiluminescent immunoassay. Outcome variables The primary variable was comparative analysis of antibody levels and clinical profile of COVID-19 in cases and controls. The secondaryvariable was association of the severity of COVID-19 with the antibody titers produced. Results Symptomatic individuals among cases (n=12) were significantly lesser than controls (n=22) (p=0.009). The median IgG titers of cases and controls were comparable at six weeks (p=0.40), but the titers were significantly lower for cases at 12 weeks (p=0.011) and 24 weeks (p=0.006). There was significant fall in titers from 6 to 12 and 24 weeks in both the groups. The titers were not affected by COVID-19 severity and pre-existing comorbidities. Conclusion Patients with TDT manifest with mild or asymptomatic COVID-19 and mount a comparable IgG antibody response to COVID-19 akin to controls. However, this serological response could not sustain over three to six months advocating the need for protection through vaccination.

[1]  I. Thuret,et al.  SARS-CoV-2 infection in patients with β-thalassemia: The French experience , 2021, Transfusion Clinique et Biologique.

[2]  A. Taher,et al.  SARS‐CoV‐2 infection in patients with β‐thalassemia: Experience from Lebanon , 2021, American journal of hematology.

[3]  R. Paredes,et al.  Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes , 2021, Med.

[4]  G. Wogan,et al.  Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset , 2021, Proceedings of the National Academy of Sciences.

[5]  D. Stuart,et al.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.

[6]  N. Curtis,et al.  Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections , 2020, Archives of Disease in Childhood.

[7]  Z. Livneh,et al.  Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation , 2020, EClinicalMedicine.

[8]  D. Devine,et al.  The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19 , 2020, Blood Advances.

[9]  F. Piel,et al.  Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients , 2020, Haematologica.

[10]  T. Zarei,et al.  Prevalence and Severity of Coronavirus Disease 2019 (COVID-19) in Transfusion Dependent and Non-Transfusion Dependent β -Thalassemia Patients and effects of Associated Comorbidities: An Iranian Nationwide study , 2020, Acta bio-medica : Atenei Parmensis.

[11]  D. Farmakis,et al.  COVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation , 2020, European journal of haematology.

[12]  J. Erdmann,et al.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.

[13]  M. Cappellini,et al.  SARS‐CoV‐2 infection in beta thalassemia: Preliminary data from the Italian experience , 2020, American journal of hematology.

[14]  Lei Liu,et al.  Relationship between the ABO Blood Group and the COVID-19 Susceptibility , 2020, medRxiv.

[15]  Zhaofeng Chen,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[16]  Rui Ji,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[17]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[18]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[19]  V. Pinto,et al.  Sickle cell disease: a review for the internist , 2019, Internal and Emergency Medicine.

[20]  M. Naderi,et al.  The Role of Immune System in Thalassemia Major: A Narrative Review , 2017 .

[21]  R. Marwaha,et al.  Immune functions in splenectomized thalassaemic children , 2000, Indian journal of pediatrics.

[22]  E M Walker,et al.  Effects of iron overload on the immune system. , 2000, Annals of clinical and laboratory science.

[23]  J. Dwyer,et al.  Behaviour of human immunoregulatory cells in culture. I. Variables requiring consideration for clinical studies. , 1979, Clinical and experimental immunology.

[24]  P. Kozinn,et al.  INFECTION AND IRON OVERLOAD IN THALASSEMIA 1 , 1969, Annals of the New York Academy of Sciences.

[25]  UP Ghaziabad.  MINISTRY OF HEALTH & FAMILY WELFARE GOVERNMENT OF INDIA , 2016 .

[26]  M. Cappellini,et al.  Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) , 2014 .

[27]  E. Vichinsky,et al.  Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT) , 2013 .

[28]  D. Farmakis,et al.  Pathogenetic aspects of immune deficiency associated with beta-thalassemia. , 2003, Medical science monitor : international medical journal of experimental and clinical research.